Archives: Agenda

• Demystifying the language of AI to assess whether it’s really the right solution for your study
• Concrete use cases for its successful and unsuccessful implementation
• Addressing concerns of inherent bias in data and increased data security and privacy fears
• What systems and vendors are on the market, and assessing their offerings for your specific data needs

• A roadmap to future proofing clinical data management: Implementing agile approaches to optimize stale workflows
• What will the growth of new clinical software vendors look like, and what will their offerings be?
• Scaling EDC and other systems to lead to the development of an integrated e-clinical environment and contribute to operational successes
• Ways in which today’s competitive pressures can push the industry to seek improved drug development strategies and shorten timelines

• Moving away from fragmented data and towards simplified pathways and what are the tools needed to facilitate data alignment?
• A look at Johnson&Johnson’s newly built platform to handle different data formats
• Ways to work together as an industry to hep standardize current processes
• Adapting to increased data sources and understanding the roadblocks to consolidating disparate data
• How can biotechs reliably minimize data risk and maximize data quality when combining different data sources?

Interactive roundtable sessions offer a unique opportunity to come together with your peers to share best practice and develop solutions to critical challenges facing the industry as a whole. Each discussion will be led by a table moderator and will focus on a different challenge within rare disease clinical trials.

Roundtables are an exciting, interactive way to build your personal network and learn from the experience and expertise of others. After 45 minutes, delegates will have the opportunity to swap and choose a different table, and each roundtable will run twice.

Roundtable 1: Sharing experiences and highlighting importance of decentralizing in rare disease trials

Leila Cupersmith, Rare Disease Clinical Trial Expert & Patient Advocacy

Roundtable 2: Overcoming patient retention challenges in rare disease trials

Jenifer Waldrop, Executive Director, Rare Disease Diversity Coalition

Roundtable 3: Using new technologies in rare disease trials

Bruce Bloom, Chief Collaboration Officer, Healx